Cytokinetics, Incorporated (NASDAQ:CYTK – Get Free Report) CEO Robert I. Blum sold 22,500 shares of the company’s stock in a transaction that occurred on Monday, June 17th. The stock was sold at an average price of $52.60, for a total transaction of $1,183,500.00. Following the completion of the transaction, the chief executive officer now owns 416,645 shares in the company, valued at $21,915,527. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at this hyperlink.
Cytokinetics Stock Down 2.1 %
Shares of CYTK stock opened at $52.78 on Tuesday. The stock has a fifty day moving average of $60.35 and a 200 day moving average of $65.94. Cytokinetics, Incorporated has a 52 week low of $25.98 and a 52 week high of $110.25. The firm has a market capitalization of $5.53 billion, a price-to-earnings ratio of -9.77 and a beta of 0.75.
Cytokinetics (NASDAQ:CYTK – Get Free Report) last announced its quarterly earnings results on Wednesday, May 8th. The biopharmaceutical company reported ($1.33) EPS for the quarter, missing analysts’ consensus estimates of ($1.16) by ($0.17). The company had revenue of $0.84 million during the quarter, compared to the consensus estimate of $0.91 million. During the same period last year, the firm earned ($1.38) earnings per share. The firm’s revenue for the quarter was down 81.8% compared to the same quarter last year. Equities research analysts anticipate that Cytokinetics, Incorporated will post -4.55 earnings per share for the current year.
Analyst Ratings Changes
Read Our Latest Report on Cytokinetics
Institutional Trading of Cytokinetics
Institutional investors and hedge funds have recently added to or reduced their stakes in the business. Assenagon Asset Management S.A. purchased a new stake in Cytokinetics in the fourth quarter worth $46,308,000. Vanguard Group Inc. lifted its position in Cytokinetics by 4.6% during the third quarter. Vanguard Group Inc. now owns 10,743,324 shares of the biopharmaceutical company’s stock valued at $316,498,000 after buying an additional 472,595 shares during the period. HealthInvest Partners AB purchased a new position in Cytokinetics during the fourth quarter valued at $980,000. Legato Capital Management LLC purchased a new position in Cytokinetics during the fourth quarter valued at $1,305,000. Finally, Vestal Point Capital LP purchased a new position in Cytokinetics during the fourth quarter valued at $4,174,000.
About Cytokinetics
Cytokinetics, Incorporated, a late-stage biopharmaceutical company, focuses on discovering, developing, and commercializing muscle activators and inhibitors as potential treatments for debilitating diseases. The company develops small molecule drug candidates primarily engineered to impact muscle function and contractility.
Read More
- Five stocks we like better than Cytokinetics
- Canadian Penny Stocks: Can They Make You Rich?
- Buffett Bails on BYD: What It Means for the Future of EV Stocks
- How to Use the MarketBeat Excel Dividend Calculator
- Domino’s vs. Papa John’s: Stock Showdown of Pizza Giants
- Stock Market Sectors: What Are They and How Many Are There?
- Williams-Sonoma Makes Stock More Accessible with a Stock Split
Receive News & Ratings for Cytokinetics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Cytokinetics and related companies with MarketBeat.com's FREE daily email newsletter.